OverviewChartNewsTraderScreen

MALIN CORP PLC/  IE00BVGC3741  /

Euronext Dublin
5/20/2024  12:00:00 AM Chg. 0.000 Volume Bid- Ask- High Low
5.900EUR 0.00% 1
Turnover: -		 -Bid Size: - -Ask Size: - 5.900 5.900
GlobeNewswire 3/11 Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting a...
GlobeNewswire 11/16/2023 Raymond and its Solutions and Support Centers Continue Pledge to Giving Back, Supporting Local Commu...
GlobeNewswire 11/9/2023 Peyto Celebrates 25 Years With Q3 2023 Results
GlobeNewswire 11/6/2023 Hammerhead Energy Inc. Announces Record Financial and Operating Results for Third Quarter 2023 and a...
TeleTrader 5/21/2022 Russia says it destroyed western arms for Ukraine
GlobeNewswire 3/9/2022 Peyto Funds Flow Rebounds in 2021
GlobeNewswire 12/14/2021 Gurnick Academy Tablet Giveaway
GlobeNewswire 12/9/2021 Gurnick Academy of Medical Arts Receives Capps' School of the Year Award
GlobeNewswire 11/23/2021 Law Firm Launches Missions-Oriented Web Series
GlobeNewswire 11/9/2021 Peyto Reports Third Quarter 2021 Results, Reinstates Monthly Dividend
GlobeNewswire 10/1/2021 McKinsey Receives Best-in-Class Distinctions in the POI 2021 Enterprise Planning Vendor Panorama Rep...
GlobeNewswire 9/23/2021 Gurnick Academy to Launch Nuclear Medicine Program
GlobeNewswire 9/2/2021 ESE Acquisition Target, Digital Motorsports, Announces Multi-Year Deal with Rising F3 Star Jack Dooh...
Newsfile Corp 8/12/2021 Fossil Fuels Far From Extinct: Oil and Gas Companies See Record Revenues
GlobeNewswire 8/11/2021 Peyto Reports Second Quarter 2021 Results
GlobeNewswire 5/12/2021 Peyto Posts Strong Q1 2021 Profits
GlobeNewswire 5/4/2021 Jounce Therapeutics Reports First Quarter 2021 Financial Results
GlobeNewswire 4/28/2021 Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELEC...
GlobeNewswire 4/27/2021 Jounce Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on Tue...
GlobeNewswire 4/13/2021 Nouveau Monde Confirms Its Firm Commitment to Achieving Past, Present & Future Carbon Neutrality, by...
GlobeNewswire 4/12/2021 Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
GlobeNewswire 4/10/2021 Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Asso...
GlobeNewswire 3/12/2021 Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
GlobeNewswire 3/10/2021 Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Associati...
GlobeNewswire 3/10/2021 Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock